...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Prostaglandin D 2 generation from human lung mast cells is catalysed exclusively by cyclooxygenase-1
【24h】

Prostaglandin D 2 generation from human lung mast cells is catalysed exclusively by cyclooxygenase-1

机译:来自人肺肥大细胞的前列腺素D 2仅由环氧氧酶-1催化

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Mast cells are an exceptionally rich source of prostaglandin D 2 (PGD 2 ). PGD 2 is pro-inflammatory and can cause bronchoconstriction. The enzyme cyclooxygenase (COX) is central to the generation of prostanoids such as PGD 2 . Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX. COX exists as two isoforms, COX-1 and COX-2. The principal aim of this study was to establish whether COX-1 and/or COX-2 mediates PGD 2 generation from human lung mast cells. Mast cells were isolated from human lung tissue and purified by flotation over Percoll and immunomagnetic bead separations. The cells were activated with anti-IgE or Stem Cell Factor (SCF). The generation of PGD 2 was determined by ELISA. The effects of NSAIDs (aspirin, ibuprofen, diclofenac, naproxen, indomethacin), COX-1 selective (FR122047), and COX-2 selective (celecoxib) inhibitors on PGD 2 generation were determined. The expression of COX-1 and COX-2 in mast cells was determined by Western blotting. All the NSAIDs tested abrogated stimulated PGD 2 generation from mast cells except aspirin which was only weakly effective. FR122047 was an effective inhibitor of PGD 2 generation (EC 50 ~25nM) from mast cells whereas celecoxib was ineffective. Immunoblotting indicated that COX-1 was strongly expressed in all mast cell preparations while COX-2 expression was weak. No induction of COX-2 was observed following activation of mast cells. These findings indicate that COX-1 is the principal isoform involved in generating PGD 2 from human lung mast cells. These studies provide insight into the potential behaviour of NSAIDs in the context of respiratory diseases.
机译:摘要肥大细胞是前列腺素D 2的异常富含源(PGD 2)。 PGD​​ 2是促炎,可导致支气管混凝土。酶环氧化酶(COX)是替代前列腺醇的核心,例如PGD 2。非甾体类抗炎药(NSAID)抑制COX。 Cox存在于两种同种型,COX-1和COX-2。本研究的主要目的是建立COX-1和/或COX-2是否介导从人肺肥大细胞中产生的PGD 2。从人肺组织中分离肥大细胞,并通过浮选纯化,并通过Percoll和免疫磁珠分离纯化。用抗IgE或干细胞因子(SCF)活化细胞。 PGD​​ 2的产生由ELISA测定。确定NSAIDs(阿司匹林,布洛芬,双氯芬酸,萘酮,吲哚美辛嘧啶),COX-1选择性(FR122047)和COX-2选择性(Celecoxib)抑制剂对PGD 2产生的影响。通过蛋白质印迹测定Cox-1和Cox-2中的表达。除阿司匹林之外,所有NSAID都经过刺激的PGD 2,均为毫无效率。 FR122047是来自肥大细胞的PGD 2生成(EC 50〜25nm)的有效抑制剂,而塞克莫昔布是无效的。免疫印迹表明,在所有肥大细胞制剂中强烈表达COX-1,同时COX-2表达弱。在激活肥大细胞后,不观察到COX-2的诱导。这些发现表明COX-1是从人肺肥大细胞产生PGD 2的主要同种型。这些研究提供了对呼吸系统疾病背景下NSAIDs的潜在行为的洞察力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号